Ancillary Observational Study of Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Blinatumomab (Primary) ; Dasatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 20 Feb 2018 Planned End Date changed from 1 Jan 2023 to 1 Mar 2023.
- 20 Feb 2018 Planned primary completion date changed from 1 Jan 2023 to 1 Mar 2023.
- 20 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.